You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

thyroid cancer RET inhibitor

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Malignant Thyroid Gland Tumor, Poorly Differentiated Thyroid Gland Carcinoma, Recurrent Thyroid Gland Carcinoma Trial in Houston

Recruiting
  • Malignant Thyroid Gland Neoplasm
  • +6 more
  • Quality-of-Life Assessment
  • +3 more
  • Ann Arbor, Michigan
  • +1 more
Jan 24, 2023

NSCLC, Thyroid Tumors Trial (LOXO-260)

Temporarily not available
  • Carcinoma, Non-Small-Cell Lung
  • Thyroid Neoplasms
  • (no location specified)
Sep 20, 2022

Advanced Solid Tumor Trial (HEC169096)

Not yet recruiting
  • Advanced Solid Tumor
  • (no location specified)
Jul 6, 2022

RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET-altered Papillary Thyroid Cancer Trial in Worldwide

Active, not recruiting
  • RET-altered Non Small Cell Lung Cancer
  • +39 more
  • pralsetinib (BLU-667)
  • Phoenix, Arizona
  • +65 more
Nov 10, 2022

Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET Gene Mutation Trial in Korea, Republic of, United States (TPX-0046)

Recruiting
  • Non Small Cell Lung Cancer
  • +4 more
  • Irvine, California
  • +15 more
Mar 9, 2022

RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET-altered Papillary Thyroid Cancer Trial in Chang chun

Not yet recruiting
  • RET-altered Non Small Cell Lung Cancer
  • +3 more
  • Chang chun, Jilin, China
    Jinlin Province Cancer Hosipital
Dec 21, 2022

Thyroid Cancer, Thyroid Carcinoma, Metastatic Thyroid Cancer Trial in Boston (Selpercatinib, Sodium Iodine I-131, rhTSH)

Not yet recruiting
  • Thyroid Cancer
  • +5 more
  • Boston, Massachusetts
    Massachusetts General Hospital
Dec 20, 2022

Medullary Thyroid Cancer Trial in Cordoba, Sevilla (Pralsetinib, Cabozantinib, Vandetanib)

Not yet recruiting
  • Medullary Thyroid Cancer
  • Cordoba, Spain
  • +1 more
Jan 11, 2023

NSCLC Trial in Shanghai (SY-5007)

Recruiting
  • Non-Small Cell Lung Cancer
  • Shanghai, Shanghai, China
    Shanghai Pulmonary Hospital
Sep 4, 2023

Solid Tumor, Medullary Thyroid Cancer Trial in China (Selpercatinib)

Active, not recruiting
Has Results
  • Solid Tumor
  • Medullary Thyroid Cancer
  • Guangzhou, Guangdong, China
  • +12 more
May 9, 2022

NSCLC, Medullary Thyroid Cancer, Solid Tumor Trial in Shanghai, Tianjin (SY-5007)

Recruiting
  • Non-Small Cell Lung Cancer
  • +2 more
  • Shanghai, Shanghai, China
  • +1 more
Mar 17, 2022

ALK-positive NSCLC (NSCLC), RET-positive NSCLC (NSCLC), RET-positive Thyroid Cancer Trial in Irvine, Boston (Alectinib)

Terminated
Has Results
  • ALK-positive Non-small Cell Lung Cancer (NSCLC)
  • +2 more
  • Irvine, California
  • +3 more
Aug 30, 2021

NSCLC, Medullary Thyroid Cancer, Colon Cancer Trial in Worldwide (LOXO-292)

Recruiting
  • Non-Small Cell Lung Cancer
  • +3 more
  • Scottsdale, Arizona
  • +84 more
Oct 10, 2022

Medullary Thyroid Cancer Trial in Worldwide (Selpercatinib, Cabozantinib, Vandetanib)

Recruiting
  • Medullary Thyroid Cancer
  • Birmingham, Alabama
  • +148 more
Jan 18, 2023

HRQOL in Locally Advanced Thyroid Carcinoma

Recruiting
  • Thyroid Cancer
  • +2 more
  • Tyrosine kinase inhibitor drugs.
  • Fuzhou, Fujian, China
    Road Fuma No.420
Apr 11, 2023

Thyroid Cancer Trial in Chengdu (Tislelizumab, Anlotinib, Radiotherapy)

Recruiting
  • Thyroid Cancer
  • Chengdu, Sichuan, China
    Xingchen Peng
Dec 17, 2022

Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 Trial in Tampa

Recruiting
  • Lung Non-Small Cell Carcinoma
  • +4 more
  • Tampa, Florida
    Moffitt Cancer Center
Aug 16, 2022

Lung Cancer, Non Small Cell Lung Cancer Trial in Aurora (Amivantamab 1050mg, Amivantamab 1400mg, Amivantamab (to be determined))

Not yet recruiting
  • Lung Cancer
  • Non Small Cell Lung Cancer
  • Amivantamab 1050mg
  • +2 more
  • Aurora, Colorado
  • +2 more
Apr 25, 2023

BRAF NP_004324.2:p.V600E, BRAF V600K Mutation Present, Thyroid Gland Anaplastic Carcinoma Trial in Duarte, Columbus (Dabrafenib,

Recruiting
  • BRAF NP_004324.2:p.V600E
  • +2 more
  • Duarte, California
  • +1 more
Jan 19, 2023

Thyroid Gland Anaplastic Carcinoma, Thyroid Gland Squamous Cell Carcinoma Trial in Houston, Salt Lake City (procedure, drug,

Recruiting
  • Thyroid Gland Anaplastic Carcinoma
  • Thyroid Gland Squamous Cell Carcinoma
  • Conventional Surgery
  • +5 more
  • Stanford, California
  • +5 more
Jan 26, 2023

Refractory Thyroid Gland Carcinoma, Refractory Thyroid Gland Papillary Carcinoma, Refractory Thyroid Gland Follicular Carcinoma

Recruiting
  • Refractory Thyroid Gland Carcinoma
  • +3 more
  • 177Lu-DOTA-EB-FAPI 1 radionuclide therapy
  • +2 more
  • Xiamen, China
    The First Affiliated Hospital of Xiamen University
Nov 3, 2022

Columnar Cell Variant Thyroid Gland Papillary Carcinoma, Follicular Variant Thyroid Gland Papillary Carcinoma, Metastatic

Active, not recruiting
  • Columnar Cell Variant Thyroid Gland Papillary Carcinoma
  • +25 more
  • Laboratory Biomarker Analysis
  • +3 more
  • Torrance, California
  • +6 more
Jan 12, 2023

Locally Advanced Thyroid Gland Anaplastic Carcinoma, Metastatic Thyroid Gland Anaplastic Carcinoma, Metastatic Thyroid Gland

Not yet recruiting
  • Locally Advanced Thyroid Gland Anaplastic Carcinoma
  • +2 more
  • Chicago, Illinois
  • +1 more
Jul 7, 2022

Thyroid Carcinoma Trial in New York (Vemurafenib, serial 124I PET/CT, thyrotropin alpha)

Active, not recruiting
  • Thyroid Carcinoma
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Feb 28, 2022

Advanced Malignant Tumor, Metastatic Malignant Tumor, Recurrent Malignant Tumor Trial in Houston (Everolimus, Laboratory

Recruiting
  • Advanced Malignant Neoplasm
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 9, 2022